AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more. You can reach Angus on Signal at angus.08.

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events.

This is the web version of STAT’s popup newsletter, AACR in 30 seconds, your quick guide to the American Association of Cancer Researchers’ annual meeting. Sign up here.

As we approach the conclusion of this significant AACR event, we look forward to seeing everyone at our live event on Tuesday night. The meeting has prominently featured Revolution Medicines and KRAS. Previously, AACR sessions were largely concerned with the impact of the Trump administration on cancer research funding. This year, the new NCI director sought to ease those concerns. Continue reading for more details!

Promising Results for Revolution Medicines’ KRAS Drug

Recently, researchers collaborating with the biotech company Revolution Medicines shared remarkable findings: their experimental drug daraxonrasib more than doubled survival rates in second-line pancreatic cancer compared to chemotherapy — though this increase translates to just six additional months of median survival in this challenging disease.

STAT+ Exclusive Story